Dr. Deol on the FDA Approval of Eltrombopag in Severe Aplastic Anemia
November 17th 2018Abhinav Deol, MD, associate professor, Karmanos Cancer Institute, discusses the expanded FDA approval of eltrombopag (Promacta) in combination with standard immunosuppressive therapy for the treatment of newly diagnosed adult and pediatric patients 2 years and older with severe aplastic anemia.
Read More
Reviewing the Latest in Breast Cancer and Myeloma: Drs Tarantino and Raje
Tucidinostat Plus R-CHOP Improves EFS in DLBCL Expressing MYC and BCL2
Abemaciclib/Fulvestrant Boosts PFS in HR+/HER2– Breast Cancer Post–CDK4/6i Progression
Inavolisib Plus Palbociclib/Fulvestrant Bolsters PFS in HR+/HER2–, PIK3CA-Mutant Breast Cancer
2 Commerce Drive
Cranbury, NJ 08512